Generic Medicine Info
IV (in the treatment of premature labour): Pre-existing or risk factors for ischaemic heart disease, gestational age <22 week, conditions in which prolongation of pregnancy is hazardous, intrauterine foetal death, known lethal congenital or lethal chromosomal malformation, pulmonary hypertension. Non-IV formulation is not indicated for use in uncomplicated premature labour or threatened abortion.
Special Precautions
Patient with CV disease (e.g. arrythmia, coronary insufficiency, hypertension, heart failure), diabetes mellitus, glaucoma, hyperthyroidism, hypokalaemia, seizures. Renal impairment. Children and elderly. Pregnancy and lactation. Monitoring Parameters Monitor FEV1 peak flow, and/or other pulmonary function tests; blood pressure, heart rate, CNS stimulation; serum glucose, K and creatinine; asthma symptoms; arterial or capillary blood gases if needed; lactate, and ECG (IV).
Adverse Reactions
Significant: Hypersensitivity reactions (e.g. urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema), hypokalaemia (high doses). Cardiac disorders: Tachycardia, palpitations, chest pain. Rarely, cardiac arrythmias (e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles), myocardial ischaemia. Gastrointestinal disorders: Nausea, vomiting, mouth and throat irritation (inhalation). General disorders and administration site conditions: Weakness. Metabolism and nutrition disorders: Hyperglycaemia. Rarely, lactic acidosis (high doses). Musculoskeletal and connective tissue disorders: Muscle cramps. Nervous system disorders: Tremor, headache, dizziness, drowsiness, restlessness. Psychiatric disorders: Nervousness, irritability, insomnia. Respiratory, thoracic and mediastinal disorders: Pharyngitis, rhinitis, pulmonary oedema (parenteral). Vascular disorders: Peripheral vasodilation, flushing.
Potentially Fatal: Rarely, paradoxical bronchospasm.
Drug Interactions
Increased risk of hypokalaemia with corticosteroids, diuretics (e.g. loop, thiazide) and xanthines (e.g. theophylline). Increased vascular effects with MAOIs, tricyclic antidepressants (TCAs). May cause severe bronchospasm when used with β-blockers (e.g. propranolol). May decrease serum concentrations of digoxin.
CIMS Class
Antiasthmatic & COPD Preparations / Drugs Acting on the Uterus
ATC Classification
R03AC02 - salbutamol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03CC02 - salbutamol ; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on salbutamol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in